Department of Breast Disease, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210000, PR China.
Department of Thyroid and Mammary Gland Surgery, Yixing People's Hospital, Wuxi 214200, PR China.
Nanomedicine (Lond). 2021 Feb;16(5):391-400. doi: 10.2217/nnm-2020-0458. Epub 2021 Jan 27.
To compare the efficacy and safety of 2-weekly nanoparticle albumin-bound paclitaxel (nP) and 3-weekly docetaxel regimens as neoadjuvant systemic therapy (NST) for breast cancer. Patients (n = 201) received NST comprising either dose-dense epirubicin and cyclophosphamide followed by 2-weekly nP (n = 104) or 3-weekly courses of epirubicin and cyclophosphamide followed by docetaxel (n = 97). Higher pathological complete response rates were achieved by the nP group. Subgroup analysis showed that the nP-based regimen achieved higher pathological complete response rates in patients with triple-negative tumor cells and high Ki67 levels. However, grades 3-4 peripheral sensory neuropathies were more frequent in the nP group. The 2-weekly nP-based regimen might be a better choice of NST for patients with breast cancer.
比较每周 2 次纳米白蛋白结合紫杉醇（nP）和每 3 周 docetaxel 方案作为乳腺癌新辅助全身治疗（NST）的疗效和安全性。患者（n=201）接受 NST，包括剂量密集表柔比星和环磷酰胺，随后是每周 2 次 nP（n=104）或每 3 周 epirubicin 和环磷酰胺，随后是 docetaxel（n=97）。nP 组获得了更高的病理完全缓解率。亚组分析显示，nP 为基础的方案在三阴性肿瘤细胞和高 Ki67 水平的患者中获得了更高的病理完全缓解率。然而，nP 组更频繁出现 3-4 级周围感觉神经病变。每周 2 次 nP 为基础的方案可能是乳腺癌患者 NST 的更好选择。
